Skip to content

Sophie Pilot Implementation and Assessment

Comparing the Sophie RA-CBT System and Telemedically-delivered CBT: a Pilot Implementation Study

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03904342
Enrollment
0
Registered
2019-04-05
Start date
2021-01-31
Completion date
2021-12-31
Last updated
2020-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Cancer, Anxiety, Depression Chronic

Keywords

Cognitive behavioral therapy (CBT), Sophie CBT, iHope CBT, Consolidated Framework for Implementation Research (CFIR)

Brief summary

Evidence-based interventions using cognitive behavioral therapy (CBT) and self-management education have been demonstrated to effectively treat symptoms of depression and improve the quality of life in populations with chronic illness. Research indicates that CBT is the most effective psychosocial treatment for depression; as effective as pharmacotherapy and as effective as adding another medication for patients who do not respond to one antidepressant alone. Despite the existence of proven efficacious treatments for depression, however, fewer than half of patients for whom depression treatment is indicated receive the services they need. Access barriers (i.e., transportation, insurance coverage), limited clinician availability (i.e., long waitlists, difficulty finding a provider), and competing (and time-consuming) medical priorities contribute to inadequate depression treatment for individuals with serious chronic illness. In this research the investigators will conduct a pilot randomized trial to compare results from implementation of two CBT strategies iHope and Sophie.

Detailed description

A pre-implementation pilot study will be conducted with 20 adult patients diagnosed with advanced (Stage 3 or 4) cancer who screen positive for moderate depression and are receiving care at the Solomont Center for Hematology and Medical Oncology at Boston Medical Center (BMC) with the following specific aims: 1. Using the Consolidated Framework for Implementation Research (CFIR) as a guide, design a pilot implementation strategy for introducing the Sophie CBT system and iHope system into the clinical context of care (Months 1-4) 2. Conduct a pre-implementation pilot study with randomization of 20 cancer patients who screen positive for depression and/or anxiety into two arms with Sophie CBT or iHope telemedicine (10 participants each) to: a) assess the feasibility, acceptability, and appropriateness of implementing the Sophie CBT and iHope interventions in an ambulatory cancer treatment center and b) evaluate the potential impact of the Sophie CBT and iHope interventions on measures of depression, anxiety, coping, and quality of life for cancer patients with comorbid depression (Months 5-10)

Interventions

BEHAVIORALSophie CBT System

The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.

BEHAVIORALiHope CBT

Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.

Sponsors

Boston Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with stage 3 or 4 cancer receiving care at Solomont Cancer Center * GAD score \>10 AND/OR positive screening for moderate to severe depressive symptoms (PHQ-8\>9). * Comfortable using tablet, phone and computer * Has telephone access * Speaks English * Lives in greater Boston area

Exclusion criteria

* Patients without the capacity to provide informed consent * Ongoing substance use disorder * Patients with Schizophrenia and Dementia

Design outcomes

Primary

MeasureTime frameDescription
Change in depressive symptomsbaseline, 8 weeksChanges in depressive symptoms will be measured using the PHQ-8, which is an 8-item scale with scores ranging from 0 to 24, with higher scores indicative of more depressive symptoms

Secondary

MeasureTime frameDescription
Change in anxietybaseline, 8 weeksThe Generalized Anxiety Disorder 7 (GAD-7) will be used to assess changes in anxiety. The GAD-7 is a 7-item questionnaire that asks how often an individual has been bothered by a given item over the last 2 weeks. Scores range from 0 (not at all) to 3 (nearly every day.) A higher overall score indicates a greater level of anxiety.
Change in copingbaseline, 8 weeksChanges in coping will be assessed using the Ways of Coping scale which is a 66 item scale with potential responses from 1 to 4, with higher scores indicative of more frequent use of a particular strategy.
Changes in quality of lifebaseline, 8 weeksChanges in quality of life will be assessed using the Quality of Life Scale (QOLS), which is a 15-item scale with potential responses ranging from 1 to 7, with higher scores indicating a higher level of satisfaction with quality of life.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026